Novo Nordisk A/S : VictozaR label in the US updated to include data showing superior efficacy when compared to JanuviaR | Reuters

Novo Nordisk A/S : VictozaR label in the US updated to include data showing superior efficacy when compared to JanuviaR | Reuters

Label update also includes FDA approval of combination therapy with basal insulin for the treatment of adults with type 2 diabetes

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved to update the product label for Victoza^R (liraglutide [rDNA] injection) to include data showing superior blood sugar control and weight reduction when compared to Januvia^R (sitagliptin).